Who Optimizes SG&A Costs Better? Soleno Therapeutics, Inc. or Evotec SE

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive landscape of the pharmaceutical and biotechnology sectors, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Evotec SE and Soleno Therapeutics, Inc. have demonstrated contrasting strategies in optimizing these costs. From 2014 to 2023, Evotec SE's SG&A expenses surged by nearly 843%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Soleno Therapeutics, Inc. maintained a more conservative growth of approximately 362% in the same period, indicating a focus on lean operations.

Evotec SE's expenses peaked in 2023, reaching a staggering 170 million, while Soleno's highest was around 13 million. This disparity highlights Evotec's expansive strategy compared to Soleno's cautious approach. As investors and analysts evaluate these companies, understanding their SG&A trends offers insights into their operational priorities and financial strategies.